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Abstract
Background: In preclinical studies, the expression of vascular endothelial growth factor (VEGF) in hormone receptor-
positive breast cancer is associated with estrogen-independent tumor growth and resistance to endocrine therapies.
This study investigated whether the addition of bevacizumab, a monoclonal antibody against VEGF, to letrozole
enhanced the antitumor activity of the letrozole in the preoperative setting.
Methods: Postmenopausal women with newly diagnosed stage 2 or 3 estrogen and/or progesterone receptor-positive,
HER2-negative breast cancer were randomly assigned (2:1) between letrozole 2.5 mg PO daily plus bevacizumab 15mg/
kg IV every 3 weeks (Let/Bev) and letrozole 2.5mg PO daily (Let) for 24 weeks prior to definitive surgery. Primary objective
was within-arm pathologic complete remission (pCR) rate. Secondary objectives were safety, objective response, and
downstaging rate.
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Results: Seventy-five patients were randomized (Let/Bev n = 50, Let n = 25). Of the 45 patients evaluable for pathological
response in the Let/Bev arm, 5 (11%; 95% CI, 3.7–24.1%) achieved pCR and 4 (9%; 95% CI, 2.5–21.2%) had microscopic
residual disease; no pCRs or microscopic residual disease was seen in the Let arm (0%; 95% CI, 0–14.2%). The rates of
downstaging were 44.4% (95% CI, 29.6–60.0%) and 37.5% (95% CI, 18.8–59.4%) in the Let/Bev and Let arms, respectively.
Adverse events typically associated with letrozole (hot flashes, arthralgias, fatigue, myalgias) occurred in similar frequencies
in the two arms. Hypertension, headache, and proteinuria were seen exclusively in the Let/Bev arm. The rates of grade 3
and 4 adverse events and discontinuation due to adverse events were 18% vs 8% and 16% vs none in the Let/Bev and
Let arms, respectively. A small RNA-based classifier predictive of response to preoperative Let/Bev was developed and
confirmed on an independent cohort.
Conclusion: In the preoperative setting, the addition of bevacizumab to letrozole was associated with a pCR rate of 11%;
no pCR was seen with letrozole alone. There was additive toxicity with the incorporation of bevacizumab. Responses to
Let/Bev can be predicted from the levels of 5 small RNAs in a pretreatment biopsy.
Trial registration: This trial is registered with ClinicalTrials.gov (Identifier: NCT00161291), first posted on September 12,
2005, and is completed.
Keywords: Preoperative therapy, Bevacizumab, Letrozole, Breast cancer, Hormone receptor-positive breast cancer,
Luminal breast cancer, Postmenopausal
Background
Angiogenesis is an integral step in tumor progression [1].
Specifically in hormone receptor-positive breast cancer, en-
hanced angiogenesis accelerated tumor growth [2], and
overexpression of the vascular endothelial growth factor
(VEGF) either by the tumor [3, 4] or stromal cells [5] was
associated with hormone-independent growth and resist-
ance to endocrine therapies. An interplay between estro-
gens and angiogenic activity exists [6, 7], and VEGF is one
of the genes whose expression is modulated by estrogens.
Indeed, the presence of functional estrogen response
elements in the VEGF gene [8–10] underpins the transcrip-
tional activation of VEGF by estrogens [11]. Tumor-
released VEGF recruits stromal cells and promotes a des-
moplastic microenvironment; stromal cells, in turn, provide
mitogenic and angiogenic growth factors stimulating both
tumor and stromal cell growth [4]. VEGF secreted by stro-
mal cells and acting cooperatively with other factors can
substitute for estrogens and foster hormone-independent
growth of luminal tumors [5]. At the clinical level, in hor-
mone receptor-positive breast cancer, elevated intratumoral
levels of VEGF have been associated with suboptimal
responses to hormonal therapies and poorer clinical
outcomes [12–14] lending support to the hypothesis that
VEGF and angiogenesis may contribute to resistance to
endocrine therapies.
These preclinical studies set the stage for a pilot, single-
institution, single-arm study of preoperative letrozole in
combination with bevacizumab in postmenopausal women
with hormone receptor-positive breast cancer [15]. In that
study (n = 25), preoperative letrozole and bevacizumab for
24 weeks resulted in a pCR rate of 12% (n = 3), while the
overall objective response rate was 68% (n = 17). The rate
of downstaging to stage 0 or stage 1 was 32% [15]. The
treatment was overall well tolerated with an 8% discon-
tinuation rate (n = 2) due to adverse events.
The purpose of the current study was to evaluate the
benefit of neoadjuvant/preoperative bevacizumab in com-
bination with letrozole in postmenopausal women with
hormone receptor-positive breast cancer. The principal
hypothesis of the study was that concurrent inhibition of
estrogen receptor (ER)-mediated signaling and VEGF-
mediated stromal activation and angiogenesis would be
more effective than ER blockade alone. The primary object-
ive of the study was to determine the pCR rate with neoad-
juvant letrozole for 24 weeks with or without bevacizumab;
secondary objectives included assessments of toxicity, over-
all objective response, and downstaging rates in the two
arms. The utility of circulating tumor and endothelial cells
as biomarkers of response and pretreatment tumor gen-
omic profiles associated with response or resistance to
protocol therapy were explored.
Methods
Study design
This was a randomized selection (“pick-the-winner”), open-
label, two-treatment arm, phase II study conducted through
the Translational Breast Cancer Research Consortium
across nine cancer centers in the USA. Bevacizumab was
provided by Genentech. This study is registered on the clin-
ical trial website of the US National Cancer Institute
(http://www.clinicaltrials.gov/ct2/show/NCT00161291).
Patient population
Eligible patients were postmenopausal women, 50 years
or older, with newly diagnosed and pathologically con-
firmed invasive stage 2 and 3 breast cancer (T2, T3,
T4a-c, N0-2, and M0), ER- and/or PR-positive, Her2/
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neu-negative (0 or 1 by immunohistochemistry or non-
amplified by in situ hybridization; a 2+ score by immu-
nohistochemistry had to be confirmed as non-amplified
by in situ hybridization) who were candidates for mast-
ectomy or breast conserving surgery. Eligible patients
had to have measurable disease by mammogram and/or
ultrasound; in special cases, dedicated breast magnetic
resonance imaging (MRI) could be used. Patients were
required to demonstrate controlled blood pressure (<
150/90 mmHg) and a normal ejection fraction with a
multigated acquisition (MUGA) scan or echocardiogram
at baseline.
Patients with inflammatory (T4d) or metastatic breast
cancer were excluded. Other exclusion criteria consisted
of uncontrolled endocrine or cardiac disease, bilateral
breast cancer, major surgical procedure within 28 days
of initiation of therapy, history of abdominal fistula-
gastrointestinal perforation-intra-abdominal abscess, or
other malignant diseases. Co-administration of other can-
cer treatments was not allowed, and hormonal replacement
therapy had to be discontinued at least 2 weeks before the
initiation of study therapy.
Patients with positive axillary lymph nodes, either by clin-
ical examination or by fine needle aspiration, were treated
as having at least N1 disease and were not required to
undergo sentinel lymph node biopsy prior to initiation of
neoadjuvant therapy. Axillary lymph node dissection was
performed in those patients at the time of definitive surgery.
Sentinel lymph node biopsy before initiation of neoadjuvant
therapy for non-palpable nodes was performed at the dis-
cretion of the treating physician. All patients gave informed
consent. The protocol was reviewed and approved by each
participating institution, and the study followed the Declar-
ation of Helsinki and good clinical practice guidelines.
Treatment and dose modification
Patients who met the eligibility criteria and signed in-
formed consent were randomly assigned, 2:1, to daily
treatment with letrozole 2.5 mg PO and bevacizumab 15
mg/kg IV every 3 weeks (investigational arm, Let/Bev) or
daily treatment with letrozole 2.5 mg PO alone (control
arm, Let). The duration of each cycle was 3 weeks.
In the absence of treatment delays due to adverse events,
treatment continued until one of the following criteria was
met: 24 weeks of active therapy or 9 administrations of
bevacizumab, disease progression, intercurrent illness that
prevented further administration of treatment, any toxicity
that resulted in a treatment delay of > 3 weeks, unaccept-
able grade 3 or 4 non-hematologic adverse event(s), con-
sent withdrawal, and general or specific changes in the
patient’s condition that rendered unacceptable for further
continuation of treatment in the judgment of the investi-
gator. No dose modifications were allowed for both beva-
cizumab and letrozole. The maximum allowable length of
treatment interruption for bevacizumab was 6 weeks due
to the long elimination half-life of the agent. An interval of
at least 4 weeks between the last administration of bevaci-
zumab and definitive surgery was required while letrozole
was continued until the day before surgery.
Assessments for safety and efficacy
Patients were monitored for safety and tolerability
throughout and after completion of protocol treatment.
Toxicity was assessed using the National Cancer Institute
Common Terminology Criteria for Adverse Events version
3.0. Physicians’ visits and physical examinations were per-
formed every 6 weeks; laboratory evaluations were per-
formed every 3 weeks in the investigational arm (including
a urine protein/creatinine ratio or urine dipstick) and every
6 weeks in the control arm. Study procedures included
evaluation of cardiac function at screening and week 24
with echocardiogram or MUGA scan.
At study enrollment, the surgeons were required to
state the planned definitive surgery that the patient
would have required without preoperative treatment.
The type of definitive surgery that the patient underwent
after preoperative protocol therapy was recorded.
At 6, 12, ad 18 weeks, patients underwent evaluation of
response by physical examination and breast ultrasound.
Patients with objective response or stable disease (SD)
according to the Response Evaluation Criteria in Solid
Tumors (RECIST [16]) continued the same regimen for a
maximum of 24 weeks or until progression was observed.
Patients with progressive disease (PD) at any time were re-
moved from the protocol and were treated at the investiga-
tor’s discretion. At week 24, the evaluation before surgery
included a physical evaluation, a breast ultrasound, and a
mammogram. Post-surgical adjuvant therapy was adminis-
tered at the investigator’s discretion.
pCR was defined as the absence of any residual invasive
cancer in the resected breast specimen and all sampled ipsi-
lateral lymph nodes (i.e., ypT0/is ypN0) adopting the defin-
ition proposed by the FDA [17]; microscopic residual
disease was defined as < 5mm residual invasive cancer in
the breast (ypT1mi or ypT1a) and isolated or no tumor cell
clusters in the ipsilateral axillary lymph nodes (ypN1mi
or ypN0).
Imaging responses were assessed according to RECIST
[16] by breast ultrasound or breast MRI in selected cases
(whichever modality was consistently obtained through-
out the treatment period and most accurately assessed
the status of the tumor). Comparisons were made with
the same imaging modality in every patient. Pathologic
responses were assessed by comparing the maximum cu-
mulative diameter of the target lesion(s) at the time of
diagnosis as assessed by imaging studies with the size of
the tumor in the final surgical pathology.
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Circulating tumor cells
Levels of circulating tumor cells (CTCs) and circulating
endothelial cells (CECs) in the peripheral blood prior to
treatment (baseline) and during treatment at weeks 6, 18,
and 24 were assessed. The number of CTCs in 7.5mL of
blood was measured using the CellSearch system (Veridex
LLC, Raritan, NJ, USA) [18]. CTCs were defined as
EPCAM-positive nucleated cells expressing cytokeratins
but not the leukocyte common antigen CD45 [19]. In a few
cases, e.g., when the available blood volume was below 7.5
mL, we performed CTC enumeration using an EPCAM-
based immumomagnetic enrichment and flow cytometry
procedure [20]. In this assay, CTCs were defined as nucle-
ated EPCAM-positive and CD45-negative. In order to com-
bine the data from the two assays, we reported the CTC
values as CTC per mL of blood.
The number of CECs in 50 μL of blood was measured
using a four-color flow cytometric assay performed on
FACS Calibur (BD Biosciences, San Jose, CA, USA) [21].
CECs were defined as nucleated, CD34-positive, CD31-
positive, and CD45-negative. Other CEC-related popula-
tions (CD34-positive and CD45-negative) were also eval-
uated including (1) nucleated and CD146-positive CECs,
(2) activated CECs (CD105-positive and CD31-positive),
(3) progenitor CECs (CD133-positive and CD31-
positive), and (4) CD146-positive and CD31-positive
CECs. CEC values were reported as CEC per microliter
of blood.
Biopsies of primary tumors
Core biopsies (research biopsies) of the primary breast
tumor were obtained at baseline and on week 6 after ini-
tiation of therapy. Biopsy samples were obtained using a
14–18 gauge core needle. At least three core biopsies
were obtained, two snap frozen individually and a third
one was taken for the preparation of paraffin-embedded
blocks. Frozen tissues were used for high-throughput
genomic analyses after macrodissection.
De-identified fresh frozen tumor tissue biopsy speci-
mens were obtained from the University of Alabama at
Birmingham’s Comprehensive Cancer Center Tissue Pro-
curement Shared Facility. The specimens were macrodis-
sected by a board-certified pathologist at the Tissue
Procurement Shared Facility to enrich for tumor cell con-
tent and remove adjacent uninvolved tissue. The dissected
specimens were weighed and transferred to a 15-mL con-
ical tube containing ceramic beads, and RLT Buffer (Qia-
gen) plus 1% BME was added so that the tube contained
35 μL of buffer for each milligram of tissue. The conical
tubes containing tissue, ceramic beads, and buffer were
agitated in a MP Biomedicals FastPrep machine at 6.5 m/s
for 90 s to homogenize the tissue. The homogenized tissue
was stored at − 80 °C. Total RNA was extracted from
350 μL of tissue homogenate (equivalent to 10mg of
tissue) using the Norgen Animal Tissue RNA Purification
Kit (Norgen Biotek Corporation). Cell lysate was treated
with Proteinase K before it was applied to the column and
on-column DNAse treatment was performed according to
the manufacturer’s instructions. Total RNA was eluted
from the columns and quantified using the Qubit RNA
Assay Kit and the Qubit 2.0 fluorometer (Invitrogen). We
used 70 ng of the purified total RNA for most samples.
Small RNA libraries were created as described previously
[22] except that no blocking of any small RNA species
was performed. In short, small RNA samples had adaptor
oligonucleotide ligated to both ends. cDNA was created
by reverse transcription and amplified by 15 cycles of
PCR. PCR products were purified and run under extreme
denaturing conditions on acrylamide gels. Bands corre-
sponding to libraries with insert sizes of 15–30 base pairs
were excised and purified. The libraries were sequenced
on a HiSeq 2500 (Illumina).
For qPCR assays, 4 μl of purified RNA for each sample
was subjected to reverse transcription using the Univer-
sal cDNA Synthesis Kit II (Exiqon). Resulting cDNA was
diluted 1:20 and combined with primers and 2X Power
SYBR mix (ThermoFisher). The primers were obtained
from Exiqon (Supplementary Appendix). The qPCR re-
actions were run on a QuantStudio 6 Flex under default
conditions. CT values were called using the QuantStudio
software with default settings.
Statistical considerations
The trial was sized to estimate the within-arm pCR rates
to a certain precision; it was not powered to compare
arms. Based on a prior pCR rate of 12% in the investiga-
tional arm of our pilot trial [15], with n = 50, this trial
had a standard error of ± 0.052 and, using the Blyth-
Still-Casella method, provided a pCR rate and two-sided
confidence interval of 5.4–23.3%. In the control arm,
with n = 25 and projected pCR rate of < 1% [23–25], no
pCR events were anticipated and the probability of ob-
serving one pCR event was 22%. The purpose of the
control arm was to characterize the pCR response as
similar to the prior (historical control) trials with single-
agent neoadjuvant letrozole.
Descriptive statistics were used to summarize baseline
characteristics of all patients by randomization arm in
order to assess relative comparability of the two arms of
the study. Mean, standard deviation, and range were
summarized for continuous variables, and frequencies
(percentages) were calculated for categorical variables.
The differences between the pCR and response rates
were determined along with 95% exact confidence inter-
vals (CIs). All toxicities were recorded and summarized
by calculating frequencies and proportions of toxicity
grades for each arm.
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A Student’s t test was used to examine the correlation
between response and CTC and CEC values at baseline
and at each time point for all patients and patients within
each arm. Response was categorized into binary variables,
0 for stable and progressive disease and 1 for partial and
complete response while CTC and CEC values were tested
as continuous variables. Correlation between response
and the changes in CTC and CEC numbers between base-
line and other time points and the changes between time
points were also examined. Correlations with a p value <
0.05 were considered significant.
Genomic data analyses
Raw sequencing reads were analyzed as described previ-
ously [26]. Briefly, reads were aligned to the human
whole genome (hg19) requiring perfect matches. Fea-
tures were created by merging overlapping alignments
and total read counts reported for each.
To generate a small RNA-based classifier of treatment
response, patients were categorized as responders if they
had achieved a pathologic treatment response > 30% and
non-responders if they had stable or progressive disease.
Pathologic response was assessed by comparing the max-
imum cumulative diameter of the target lesion(s) at the
time of diagnosis as assessed by imaging studies with the
size of the tumor in the final surgical pathology. Due to
the small number of patients who achieved pCR or micro-
scopic residual disease, a genomic classifier on the basis of
achievement of pCR or microscopic residual disease could
not be generated. Differential expression of feature counts
was assessed using DESeq2 [27]. From previously gener-
ated full-length RNA-seq data on these samples (data not
presented), we had quality control (QC) metrics (fraction
of reads mapping to mRNA and cDNA concentration).
Significance was assessed using a likelihood ratio test be-
tween the full (response variable + QC metrics) and null
(QC metrics) models as implemented in DESeq2.
We predicted the agreement between qPCR and sequen-
cing data using previously described methods [26]. We
evaluated the relative proportions of 3′ ends of small RNA
features, predicting that those with many, equal propor-
tioned 3′ ends would not yield concordant data between
qPCR and sequencing measurements. We then selected
small RNA features that had low p values from the likeli-
hood ratio test and were predicted to yield concordant
qPCR and sequencing measurements. We employed
LASSO regression on this subset as implemented in the R
package glmnet [28], in order to find small RNA features
with optimal ability to classify responder vs. non-responder
status. A binomial regression model to predict responder
status was created from these optimal classifiers, operating
on z-score values from both sequencing and qPCR mea-
surements. Raw CTs from qPCR measurements were
normalized using hsa-miR-22-3p. We chose this miRNA
based on its robust expression and very low variance across
samples in the small RNA sequencing data. Accuracies of
model predictions were calculated by summing the true
positives and true negatives divided by the total predic-
tions. ROC curve areas and p values were calculated using
the R package “verification.”
Results
Patients and dispositions
Patient demographics and tumor characteristics are
shown in Table 1. In the study, 75 patients were ran-
domly assigned, 50 in the Let/Bev arm and 25 in the Let
arm (2:1 ratio). All patients received at least 1 cycle of
therapy. The median age for the patients enrolled in the
Let/Bev arm was 61.4 years (range, 50.4 to 81.9) and 65
for the Let arm (range, 50.4 to 86.3). All patients had an
ECOG performance status of 0. The protocol arms were
well balanced for race, stage, nodal status, and tumor
type. The proportion of patients with grade 2 tumors
was higher in the Let arm (76% vs. 58% respectively),
while no patient with grade 3 tumors was randomized to
the Let arm (16% vs. 0% respectively). Randomization
was not stratified for any demographic or disease
parameter.
Figure 1 provides the CONSORT diagram for the
study. On the Let arm, 92% of the patients (n = 24) com-
pleted therapy, whereas 76% (n = 38) completed therapy
on the Let/Bev arm. On the Let arm, discontinuations
were due to the absence of response, whereas adverse
events were the main reasons for discontinuation in the
Let/Bev arm. As specified in the protocol, all patients
underwent surgery 4 weeks after the last dose of Bev but
continued taking Let until the day before surgery.
Efficacy
Pathologic response
Of the 50 patients enrolled in the Let/Bev arm, 45 pa-
tients had available surgical pathology for evaluation of
pathologic response (consent withdrawal, n = 2; transi-
tion to chemotherapy at the discretion of the treating
physician, n = 2; discontinuation due to toxicity, n = 1,
Fig. 1). Of the 25 patients in the Let arm, 24 patients
had available surgical pathology (1 patient refused sur-
gery upon completion of protocol therapy, Fig. 1).
As seen in Table 2 and Fig. 2a, the rates of pCR, micro-
scopic residual disease, PR, and objective response were
numerically higher in the Let/Bev arm vs. Let arm (11.1%
vs. none, 8.9%. vs none, 44.4% vs. 37.5%, and 64.4% vs.
37.5% respectively; no formal statistical testing, per proto-
col). One of the 5 patients who achieved pCR in the Let/
Bev arm had residual ductal carcinoma in situ. These data
are in agreement with the responses reported previously
in a single-arm study of letrozole and bevacizumab in the
same patient population [15]. The rates of downstaging
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(from stage 3/2 to stage 1/0) and lymph node reversion
(from positive upon diagnosis to negative at the time of
surgery) were also numerically higher in the Let/Bev arm
(44.4% vs. 37.5% and 40.0% vs. 26.6% respectively). The
rates of stable and progressive disease (disease same as or
greater than its original radiological assessment at the
time of diagnosis) were numerically lower in the Let/Bev
arm vs. Let arm (28.8% vs 50% and 6.6% vs 12.5%, respect-
ively). Of the 6 patients with progressive disease in the
trial (3 in each arm), the surgical pathology after protocol
therapy in 3 patients (Let arm, n = 2; Bev/Let arm, n = 1)
was consistent with invasive lobular carcinoma, grade 1 or
2. Given the diffuse growth pattern of cancer cells and
lack of desmoplastic reaction in invasive lobular carcin-
oma that collectively render its detection by physical
examination, imaging, and even gross pathologic evalu-
ation challenging [29], this finding may reflect clinical and
radiographic underestimation of the original extent of the
disease rather than actual tumor growth..
pCR and microscopic residual disease were seen only
in patients with grade 1 or 2 disease at diagnosis.
Additionally, all patients who achieved pCR and micro-
scopic residual disease had stage 2 disease at diagnosis.
Of the 45 patients assigned to the Let/Bev arm with
available surgical pathology, 37 were deemed at diagno-
sis to require mastectomy. Of these patients, 15 (40.5%;
95% CI, 24.8–57.9%) underwent lumpectomy following
preoperative letrozole and bevacizumab. Of the 23 pa-
tients assigned to the Let arm with available surgical
pathology (declined surgery n = 1, definitive surgery
without preoperative medical therapy not assessed n =
1), 17 were deemed at diagnosis to require mastectomy.
Of these patients, 9 (53%; 95% CI, 27.8–77%) underwent
lumpectomy following preoperative letrozole alone.
Radiological response
Forty-nine patients in the Let/Bev arm (one patient with-
drew consent before the first assessment of radiological re-
sponse due to non-protocol related issues) and 25 patients
in the Let arm were evaluable for radiological response ac-
cording to RECIST [16]; results are summarized in Table 3
and Fig. 2b. Complete, partial, and objective radiographic
Table 1 Patient characteristics
Characteristic Letrozole alone, n = 25 Letrozole/bevacizumab, n = 50 p value
Age (years)
Median (range) 65 (50.4–86.3) 61.4 (50.4–81.9) NSD
Race, n (%)
White 20 (80) 42 (84) NSD
Black 3 (12) 6 (12) NSD
Hispanic 1 (4) 2 (4) NSD
Others 1—Asian (4) –
Clinical tumor stage, n (%)
IIA 9 (36) 16 (32) NSD
IIB 7 (28) 21 (42) NSD
IIIA 9 (36) 8 (16) NSD
IIIB – 5 (10) NSD
Nodal status, n (%)
N0 9 (36) 21 (42) NSD
N+ 16 (64) 29 (58) NSD
Tumor type, n (%)
Invasive ductal carcinoma 16 (64) 29 (58) NSD
Invasive lobular carcinoma 5 (20) 13* (26) NSD
Invasive mixed carcinoma 4 (16) 7 (14) NSD
Others – 1—mucinous (2) NSD
Histologic grade, n (%)
Grade I 6 (24) 13 (26) NSD
Grade II 19 (76) 29 (58) 0.042
Grade III – 8 (16) 0.025
*Includes one patient with concurrent separate invasive mucinous carcinoma
NSD no significant difference
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Fig. 1 CONSORT diagram
Table 2 Pathologic response per protocol arm
Group Letrozole, n = 24 Letrozole/bevacizumab, n = 45
n (%) 95% CI† n (%) 95% CI†
Pathologic CR (pCR) none (0) 0, 14.2% 5^ (11) 3.7%, 24.1%
pCR and microscopic residual disease none (0) 0, 14.2% 9 (20) 9.6%, 34.7%
pCR and microscopic residual disease—(ITT)* none (0) 0, 14.2% 9 (18) 8.6%, 31.4%
Partial response 9 (37.5) 18.8%, 59.4% 20 (44.4) 29.6%, 60.0%
Objective response rate 9 (37.5) 18.8%, 59.4% 29 (64.4) 48.8%, 78.1%
Stable disease 12 (50) 29.1%, 70.9% 13 (28.8) 16.4%, 44.3%
Progressive disease 3 (12.5) 2.7, 32.4% 3 (6.6) 1.4%, 18.3%
Downstage (3/2 to 0/1) 9 (37.5) 18.8%, 59.4% 20 (44.4) 29.6%, 60.0%
Node reversion
(positive to negative)
4/15 (26.6) 7.8%, 55.1% 10/25 (40) 21.1%, 61.3%
†Exact (Clopper-Pearson) confidence interval
^One of the 5 patients who achieved a pCR had residual ductal carcinoma in situ
*ITT (intention to treat population): this analysis assumes that none of the patients who did not undergo surgery (letrozole group, n = 1; letrozole/bevacizumab
group, n = 5) achieved a pCR or microscopic residual disease
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response rates were numerically higher in the Let/Bev arm
(10% vs. 4%, 69% vs. 64%, and 79% vs. 68% respectively).
Accordingly, the rates of stable and progressive disease
were numerically lower in the Let/Bev arm vs. Let arm
(21% vs. 28% and none vs. 4%, respectively). The absolute
mean percent reduction of the maximum tumor diameter
by imaging was − 51.08% (95% CI, − 43.5 to − 58.6) in the
Let/Bev arm vs. − 39.2% in the Let arm (95% CI, − 26.4 to
− 52.2). Two patients in the Let arm and 3 in the Let/Bev
arm discontinued treatment due to inadequate clinical
response by physical evaluation and imaging; both patients
in the Let arm went for surgery without additional neoadju-
vant therapy while in the Let/Bev arm, 2 patients proceeded
to chemotherapy after completion of cycles 3 and 9 and 1
patient withdrew consent.
Safety
Twenty-five patients in the Let arm and 50 patients in
the Let/Bev arm received at least one cycle of therapy
Fig. 2 Waterfall plot of response by treatment arm. a Pathologic responses were assessed by comparing the maximum cumulative diameter of
the target lesion(s) at the time of diagnosis as assessed by imaging studies with the size of the tumor in the final surgical pathology. b
Radiological responses were assessed according to RECIST by breast ultrasound or breast MRI in selected cases (whichever modality was
consistently obtained throughout the protocol therapy and most accurately assessed the status of the tumor)
Table 3 Best radiological response per protocol arm
Best radiological responses Letrozole, n = 25 Letrozole/bevacizumab, n = 49
n (%) 95% CI† n (%) 95% CI†
Complete response (%) (no evidence of residual tumor) 1 (4) 0.1%, 20.4% 5 (10) 3.4%, 22.2%
Partial response 16 (64) 42.5%, 82.0% 34 (69) 54.6%, 81.7%
Objective response rate 17 (68) 46.5%, 85.1% 39 (79) 65.7%, 89.8%
Stable disease 7 (28) 12.1%, 49.4% 10 (21) 10.2%, 34.3%
Progressive disease 1 (4) 0.1%, 20.4% 0 (0) 0, 7.3%
Mean tumor maximum diameter change − 39% − 26.4, − 52.2 − 51% − 43.5, − 58.6
†Exact (Clopper-Pearson) confidence interval
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and were eligible for toxicity evaluation. The majority of
adverse events were grades 1 and 2.
As summarized in Table 4, the most common adverse
events observed in more than 5% of the patients in the
Let arm deemed by the investigators to be possibly re-
lated to the aromatase inhibitor were hot flashes (28%),
arthralgias/joint stiffness (24%), fatigue (16%), myalgias/
cramps (12%), nausea/vomiting (8%), and night sweats
(8%). No grade 4 toxicity was seen in the Let arm and
only 2 patients (8%) had grade 3 arthralgias/joint stiff-
ness. No patient discontinued the medication in the
letrozole alone arm due to toxicity.
Adverse events known to be associated with letrozole
were observed in similar frequencies in both arms. As
expected, there was additive toxicity in the Let/Bev arm
as adverse events known to be associated with bevacizu-
mab were observed. The most common adverse events
observed in more than 5% of the patients in the Let/Bev
arm deemed by the investigators to be possibly related
to the protocol agents were arthralgias/joint stiffness
(26%), hot flashes (18%), fatigue (14%), myalgias/cramps
(6%) possibly attributable to letrozole; hypertension
(32%), hemorrhagic and thrombotic events (16%, in-
cludes epistaxis (grade 1, n = 1; grade 2, n = 1), bleeding
gingivae (grade 1, n = 1), hematoma (grade 1, n = 1), rec-
tal bleeding (grade 1, n = 1), cerebrovascular ischemia
(grade 3, n = 1), hematemesis (grade 3, n = 1), and syn-
cope (grade 3, n = 1)), headache (14%), proteinuria
(10%), dyspnea (10%), and rash (8%), possibly attribut-
able to bevacizumab. The most frequent grade 3 adverse
events seen in the Let/Bev arm were hypertension (8%),
arthralgias/joint stiffness (4%), and proteinuria (2%).
Only 1 patient had grade 4 toxicity in the combination
arm which was proteinuria (2%). Seven patients discon-
tinued therapy in the Let/Bev arm due to adverse events,
but pathology was available after the surgical procedure:
1 patient developed necrosis followed by infection at the
site where the dye for sentinel lymph node mapping was
injected (protocol therapy discontinued on cycle 5); 3
patients had proteinuria (grades 2, 3, and 4, n = 1 each)
and received 6, 6, and 8 cycles, respectively; 1 patient
had allergic reaction to the infusion and received 5 cy-
cles; 1 patient had grade 3 fatigue and received 8 cycles;
and 1 patient had activation of a Sjögren syndrome and
received 4 cycles. In addition, one patient discontinued
therapy in the Let/Bev arm due to grade 3 cerebrovascu-
lar ischemia but surgical pathology was not available. No
healing problems at the time of surgery were seen.
Three serious adverse events were reported in the Let/
Bev arm which were classified by the investigators as pos-
sibly related to the protocol therapy: 1 patient was admitted
with confusion to the hospital due to a possible TIA (pa-
tient continued therapy), 1 patient had a neck abscess
which required admission to the hospital for IV antibiotics,
and 1 patient had grade 3 cerebrovascular ischemia (patient
was taken off study). This last patient had presented with
expressive aphasia. Thorough workup did not reveal acute
infarct, mass, or intracranial hemorrhage. Echocardiogram
was consistent with moderate to severe aortic stenosis. Her
hospital stay was extended to provide adequate blood pres-
sure control (blood pressure was 220/90mmHg at presen-
tation). On follow-up, there were no residual neurologic
Table 4 Adverse events of any grade seen in > 5% of patients in either protocol arm
Letrozole, n = 25 Letrozole/Bevacizumab, n = 50
Number of patients (percent)
Adverse events Any grade Grade≥ 3 Any grade Grade≥ 3
Hot flashes 7 (28) 0 9 (18) 0
Arthralgia/joint stiffness 6 (24) 2 (8) 13 (26) 2 (4)
Fatigue 4 (16) 0 7 (14) 1 (2)
Myalgias/cramps 3 (12) 0 3 (6) 0
Nausea/vomiting 2 (8) 0 1 (2) 0
Night sweats 2 (8) 0 2 (4) 0
Mood swings/anxiety/agitation 1 (4) 0 3 (6) 0
Vaginal dryness 1 (4) 0 3 (6) 0
Hypertension 1 (4) 0 16 (32) 4 (8)
Hemorrhagic and thrombotic events 0 0 8 (16) 3 (6)
Headache 1 (4) 0 7 (14) 0
Proteinuria 0 0 5 (10) 2 (4)
Dyspnea 1 (4) 0 5 (10) 0
Skin (rash, discoloration, pruritus) 2 (8) 0 4 (8) 0
Lower extremity edema 0 0 3 (6) 0
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symptoms. No deaths associated with the treatment agents
were seen in the trial.
Circulating tumor cells and circulating endothelial cells
CTCs were detected only in 14% of the patients. The
mean number of circulating tumor cells was 0.05/mL
(SD 0.24, range 0–1.7). Due to the limited number of pa-
tients with CTCs, the numbers at baseline and other
time points as well as the change in CTCs between time
points did not show a statistically significant correlation
with response (data not shown).
Samples for CEC analysis at baseline were available in
77% of the patients (Supplementary Table 1). At base-
line, the mean number of CD31+ CECs was 20.6 cells/
μL (standard deviation [SD] 63.0, range 2.7–489.3);
CD146+ CECs, 2.9 cells/μL (SD 3.2, range 0–13.9); acti-
vated CECs (CD105+/CD31+cells), 12.9 cells/μL (SD
44.4, range 1.2–296.2); progenitor CECs (CD133+/
CD31+), 0.8 cell/μL (SD 1.6, range 0–9.7); and CD146+/
CD31+ CECs, 0.7 cell/μL (SD 2.5, range 0–18.5). Abso-
lute numbers and changes in CEC levels did not show
significant correlation with response when all patients,
regardless of the treatment arm in which they were en-
rolled, were considered (Supplementary figure 1). How-
ever, in the Let/Bev arm, we observed a statistically
significant correlation between response and the levels
of activated CECs (CD105+/CD31+) at week 18 (p =
0.0432). In addition, changes in the levels of activated
CECs (CD105+/CD31+) (p = 0.0038), progenitor CECs
(CD133+/CD31+) (p = 0.0120), and CD146+/CD31+
CECs (p = 0.0087) between weeks 6 and 18 significantly
correlated to response.
Generation of a small RNA classifier that predicts
response to letrozole plus bevacizumab
Macrodissected tumor tissue from research biopsies ob-
tained at the time of diagnosis was successfully sequenced
in 26 and 15 patients assigned to Let/Bev and Let arms re-
spectively. Differential gene expression analyses yielded a
large number of small RNAs to be significantly associated
with response to letrozole/bevacizumab. hsa-mIR-187-3p
was the highest ranking differentially expressed small RNA
between responders and non-responders to Let/Bev in
terms of significance (Supplementary Appendix). Increased
hsa-mIR-187-3p expression in breast cancer has been asso-
ciated with an aggressive, invasive phenotype and has been
shown to be an independent predictor of outcome [30]. To
overcome the biases associated with small RNA library
preparations and the complexities of genomic data analyses,
we filtered for small RNAs likely to reproduce the sequen-
cing data when measured by qPCR (see the “Methods” sec-
tion). We identified a set of five small RNAs as an optimal
letrozole/bevacizumab classifier by LASSO regression
(Fig. 3a). These include two miRNAs (hsa-miR-141-5p,
hsa-miR-449), two small nucleolar RNAs (SNORD51,
SNORA21), and fragments of 7SK RNA. hsa-mIR-187-3p
was not predicted to generate qPCR data concordant with
sequencing measurements.
To confirm the sequencing data for these five candi-
date classifier small RNAs, we measured them in the
same set of samples by qPCR. We found a significant
agreement (p < 0.01) between sequencing and qPCR data
for all but one (SNORA21, Supplementary Figure 2). To
evaluate their performance as classifiers of response to
letrozole/bevacizumab in both types of measurement
(sequencing and qPCR), we z-scored the sequencing data
and created a binomial regression model comprising the
five LASSO-selected small RNAs. When we applied the
classifier to the sequencing data that it was trained on,
the classifier had perfect performance (ROC AUC = 1,
p = 7.1 × 10−6). We then applied the classifier to z-scored
qPCR data from the same training samples and observed
that the classifier still performed well (ROC AUC =
0.934, p = 6.2 10−5, accuracy = 0.885; Fig. 3b). We chose
a threshold for calling responders in this data set that
maximized model accuracy (Fig. 3b).
As a robust verification of the classifier, we applied it
to z-scored qPCR data from breast tumor samples col-
lected from patients that received the same treatment
(letrozole/bevacizumab) in a separate independent clin-
ical trial [15]. We successfully sequenced 16 macrodis-
sected tumor samples from the validation cohort. We
observed good performance of the classifier in these
samples as well (Fig. 3b), with only moderate decrease in
performance metrics (ROC AUC = 0.836, p = 9.0 × 10−3,
accuracy = 0.875). Lastly, we applied the model to pa-
tients from the main trial that received letrozole alone to
evaluate the specificity of the classifier for the letrozole/
bevacizumab combination, rather than for letrozole
alone. We observed non-significant performance of the
classifier on patients who received letrozole alone (ROC
AUC = 0.53, p = 0.44, accuracy = 0.467; Fig. 3b).
Discussion
The addition of bevacizumab to letrozole capitalizes on
multiple lines of evidence that implicate VEGF and angio-
genesis as major mediators of resistance to endocrine ther-
apies in luminal breast cancer [2–6, 13–15]. This study met
its primary endpoint by determining the pCR rate of neoad-
juvant/preoperative letrozole in combination with bevacizu-
mab for 24 weeks to be 11.1% (CI, 3.7–24.1%) (20%
including pCR rates and rates of microscopic residual dis-
ease). This pCR rate is highly similar to the 12% observed
in our pilot study conducted in the same patient population
[15] and at least comparable to the pCR rate achieved with
neoadjuvant anthracycline-taxane-based chemotherapy
[31]. To our knowledge, this pCR rate is the highest
reported in endocrine-based neoadjuvant clinical trials,
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exceeding the < 10% pCR rate reported in other preopera-
tive studies combining endocrine therapy with growth fac-
tor pathway inhibitors [32]. In neoadjuvant trials that
compared letrozole with or without taselisib and with or
without everolimus, the pCR rate in the combination arm
was 1.8% [25] and 1.4% [23], respectively. Similarly, the
pCR rates of preoperative combinations of endocrine ther-
apy with CDK4/6 inhibitors have been low (0% [33] and
3.8% [34]) as well. No pCR or microscopic residual disease
was seen in the control arm, and this result is consistent
with multiple prior trials with preoperative aromatase in-
hibitors. It should be noted that our study was not powered
for direct comparisons between arms and a larger study will
be required to further confirm these results.
Interestingly, pCRs were confined to patients with
stage 2 and well to moderately differentiated tumors.
The presence of established angiogenesis in larger tu-
mors promoted and sustained by multiple growth factors
may underpin this observation. Indeed, in preclinical
studies, anti-VEGF therapies have been shown to prefer-
entially target smaller peripheral blood vessels while cen-
trally located large vessels were spared [35].
Although the toxicities in the investigational arm were
not synergistic, the addition of bevacizumab did result in
a set of adverse events, known to be associated with bev-
acizumab, including hypertension, proteinuria, and
hemorrhagic and thrombotic events. The nature and fre-
quencies of the bevacizumab-associated adverse events
in this study were very similar to the ones reported in
other studies of bevacizumab combined with endocrine
therapy [36–38]. We should acknowledge the uniformly
very good performance status at baseline, generally fa-
vorable prognosis, and absence of residual toxicities
from prior therapies in this population as well as the fa-
vorable toxicity profile of letrozole.
The achievement of pCR with preoperative therapy has
been associated with favorable long-term outcomes, and
the addition of bevacizumab to preoperative chemother-
apy has led to higher pCR rates [31, 39–41]. Notably
though, this benefit has not consistently translated into a
long-term disease-free or definitive overall survival advan-
tage [42–45]. A limitation of our study is the lack of long-
term follow-up for recurrence, survival, and toxicities as-
sociated with bevacizumab. However, the choice of post-
operative therapy was left to the physician’s discretion and
many patients with large residual disease or limited treat-
ment effect eventually received adjuvant cytotoxic chemo-












Fig. 3 a Quantile-quantile plot of small RNA p values for association with letrozole/bevacizumab response. The observed p values from the
association of small RNA expression values with letrozole/bevacizumab response (see the “Methods” section) are plotted against the null
(uniform) distribution. Small RNAs selected by LASSO regression for an optimal classifier model (see the “Methods” section) are marked by black
dots and labeled. b Classifier model performance on three cohorts. Classifier values calculated from qPCR data for each patient tumor sample (x-
axis) across three cohorts are plotted on the y-axis (see the “Methods” section). Bar color indicates responder status. The dotted line indicates the
common threshold used to calculate model accuracy. The “discovery cohort” is the cohort of patients who received letrozole/bevacizumab in the
present study. The “validation cohort” is the cohort of patients who received the same treatment in a separate independent clinical trial [15]. The
“letrozole cohort” consists of patients who received letrozole in the present study. The model was trained on sequencing data from the
discovery cohort
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better overall responses achieved with the addition of bev-
acizumab translate into better long-term outcomes re-
mains an open question. The controversies regarding
antiangiogenic therapy underscore the need to identify a
biomarker for optimal patient selection; such a biomarker
has remained largely elusive [46–48]. To address this gap
in the knowledge, in the present study, we explored the
utility of circulating tumor and endothelial cells and of a
small RNA-based genomic classifier.
The level of CTCs in these patients with early-stage hor-
mone receptor-positive breast cancer was low, in agreement
with the literature [49]. The number of CTCs before and
during treatment and the changes in levels during therapy
were not associated with response. However, the low num-
ber of patients with detectable CTCs limits meaningful con-
clusions. In contrast, CECs were detected in most patients.
Interestingly, we observed a correlation between response
to letrozole and bevacizumab and the levels of activated
CECs at week 18. Changes in the levels of certain CEC
subpopulations (activated CECs, progenitor CECs, and
CD146+/CD31+ CECs) between weeks 6 and 18 were also
significantly associated with response to letrozole and beva-
cizumab. The significance of these associations remains
unclear considering the lack of any correlations at other
time points and the limited sample size.
By contrast to the CTCs and CECs, our small RNA-
based classifier may constitute a potential biomarker
predictive of response to bevacizumab. All small RNA com-
ponents of the classifier have been implicated in the patho-
biology of breast cancer. The hsa-miR-141-5p is the less
abundant product from the same pre-miRNA with hsa-
miR-141-3p and may in fact represent a surrogate measure-
ment of hsa-miR-141-3p. Overexpression of hsa-miR-141-
3p and its family member hsa-miR-200c-3p in MDA-MB-
231 breast cancer cells promotes significant migration and
invasion and enhances VEGF-A secretion [50]. VEGF-A
neutralizing antibodies abrogate these phenotypic conse-
quences conferred by hsa-miR-141-3p and hsa-miR-200c-
3p overexpression [50]. hsa-miR-449a targets cysteine-rich
intestinal protein 2 (CRIP2) mRNA, a transcription factor
and a tumor suppressor [51]. CRIP2 interacts with the NF-
κB/p65 to inhibit its DNA-binding ability to the promoter
regions of the major pro-angiogenesis cytokines critical for
tumor progression, including VEGF [51]. Indeed, increased
expression of CRIP2 is associated with impaired tumor
angiogenesis [52]. C/D box snoRNAs (like small nucleolar
RNA, C/D box 51 (SNORD51)) and H/ACA box snoRNAs
(like small nucleolar RNA, H/ACA box 21(SNORA21)) de-
fine the target sites for 2′-O-ribose methylation and pseu-
douridylation on ribosomal RNA (rRNA), respectively [53].
To our knowledge, a direct association between small nu-
cleolar RNAs and VEGFA expression or function has not
been reported. The possibility exists though that altered
rRNA modifications introduced by the small nucleolar
RNAs may modulate the RNA affinities and translational
capabilities of the ribosomes and, consequently, prioritize
the translation of VEGF mRNA as shown with the rRNA
methyl-transferase fibrillarin [54, 55]. Lastly, 7SK snRNA
and the La-related protein LARP7 are required for the in-
tegrity of the 7SK snRNP complex [56]. This complex se-
questers the positive transcription elongation factor b (P-
TEFb). Decreased levels of LARP7 and 7SK snRNA redis-
tribute P-TEFb to the transcriptionally active super elong-
ation complex, resulting in accelerated transcription of
transcription factors that promote breast cancer epithelial-
mesenchymal transition, invasion, and metastasis [56]. Al-
though a direct association between 7SK snRNA or 7SK
snRNP and VEGFA expression or function has not been re-
ported, the possibility exists that low levels of 7SK snRNA
may allow for upregulated VEGFA transcription. Although
our small RNA-based classifier was verified in an independ-
ent cohort, incorporation of the classifier as a correlative
study in clinical trials with bevacizumab will allow for
further refinements and validation. We should note that we
also performed RNA-seq on available tumor samples but
RNA-seq data analyses did not yield significant classifiers.
Conclusion
In stage 2 and 3 hormone receptor-positive and Her2-
negative breast cancer, the achievement of pCR with
endocrine therapy combinations, including combinations
with PI3K inhibitors and CDK4/6 inhibitors has been an
elusive target. In this patient population, the addition of
bevacizumab to preoperative letrozole resulted in a pCR
rate of 11.1% (95% CI, 3.7–24.1%) at the cost of additive
toxicities. We have developed a small RNA-based classi-
fier, which, on the basis of the levels of five small RNAs
in a pretreatment biopsy, can select patients more likely
to respond to bevacizumab.
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Additional file 1. Supplementary Figure 1 Changes in circulating
endothelial cells (CECs) during protocol therapy. Enumeration at baseline
and at weeks 6, 18, and 24 of circulating endothelial cells (CECs) and
related populations in blood samples collected from all patients assigned
in both protocol arms. Absolute numbers and changes in CEC levels did
not significantly correlate with response.
Additional file 2 Supplementary Figure 2 Comparison of small RNA
sequencing data to qPCR. Upper panels. For the 5 small RNAs selected as
the optimal classifier by LASSO, we plotted sequencing values (“vsd” for
variance stabilized data by DESeq2, x-axis) versus qPCR data (-dCt, y-axis).
The R-squared and p-value of the goodness-of-fit by linear regression are
provided for each small RNA. Lower panels. Boxplots for each measure-
ment type (qPCR: “-dCt”; sequencing: “vsd”) for each small RNA selected
as the optimal classifier by LASSO between non-responders and re-
sponders to letrozole/bevacizumab. The p-values are from linear regres-
sion for qPCR data (“-dCt” y-axis) and from DESeq2 (“vsd” y-axis) for
sequencing data.
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Additional file 3. Supplementary Table 1 CEC enumeration in all trial
participants.
Additional file 4. Appendix 1. LASSO selected classifiers and qPCR assay
information.
Additional file 5. Appendix 2. Summary statistics for all tested small
RNA features in sequencing data (sorted by letozole/bevacizumab
responder P).
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